| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD59A |
| Uniprot No | P13987 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-102aa |
| 氨基酸序列 | MASMTGGQQMGRGHHHHHHGNLYFQGGEFALVQCYNCPNPTADCKTAVNC SSDFDACLITKAGLQVYNKCWKFEHCNFNDVTTRLRENELTYYCCKKDLC NFNEQLEN |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD59A重组蛋白的模拟参考文献(内容基于常见研究方向整合，非真实文献)：
1. **"Expression and Functional Characterization of Recombinant Human CD59 in HEK293 Cells"**
- 作者：Smith J, et al.
- 摘要：研究通过哺乳动物表达系统(HEK293)重组表达人CD59蛋白，分析其糖基化修饰对补体抑制活性的影响，证实糖基化对蛋白稳定性及功能的关键作用。
2. **"Bacterial Expression and Purification of Mouse CD59A for Structural Studies"**
- 作者：Li X, et al.
- 摘要：利用大肠杆菌系统表达小鼠CD59A重组蛋白，通过优化纯化工艺获得高纯度蛋白，并解析其晶体结构，揭示其与补体C8/C9结合的分子机制。
3. **"Recombinant CD59A Protects Neuronal Cells from Complement-Mediated Lysis in Neuroinflammatory Models"**
- 作者：Wang Y, et al.
- 摘要：评估重组CD59A在神经炎症疾病模型中的保护作用，证明其通过抑制补体膜攻击复合物形成，减少神经元损伤，提示其治疗潜力。
4. **"Engineering a Soluble Form of CD59A for Therapeutic Applications in Autoimmune Disorders"**
- 作者：Brown K, et al.
- 摘要：通过基因工程技术改造小鼠CD59A，开发可溶性重组蛋白变体，并在体外和动物模型中验证其抑制补体过度激活的能力，为自身免疫病治疗提供新策略。
(注：以上文献为示例性内容，实际研究需参考真实数据库如PubMed、Web of Science。)
CD59A, also known as CD59 glycoprotein or protectin, is a membrane-anchored regulatory protein that plays a critical role in inhibiting the complement system's terminal pathway. As a key complement defense protein, it prevents the formation of the membrane attack complex (MAC) by binding to C8 and C9 components during MAC assembly on host cell surfaces. This activity protects human cells from unintended complement-mediated lysis, making CD59A essential for maintaining cellular integrity in physiological conditions.
The recombinant CD59A protein is produced through genetic engineering techniques, typically expressed in mammalian cell systems (e.g., CHO cells) or bacterial systems using E. coli. The recombinant form retains the functional domain of native CD59 (60-77 amino acid residues in the mature protein) while often being engineered without the glycosylphosphatidylinositol (GPI) anchor for improved solubility and purification. This modification allows researchers to study its inhibitory mechanism and therapeutic potential more effectively.
In research applications, recombinant CD59A serves as a valuable tool for investigating complement-related disorders such as paroxysmal nocturnal hemoglobinuria (PNH), age-related macular degeneration, and ischemia-reperfusion injuries. Therapeutic development focuses on its potential for treating complement-mediated diseases, either through direct administration or as a fusion protein construct. Recent studies also explore its role in immune modulation beyond complement regulation, including possible interactions with T-cell receptors and signaling pathways in inflammatory conditions.
The production of recombinant CD59A has enabled structural studies using X-ray crystallography and NMR, revealing its characteristic disc-shaped β-sandwich fold stabilized by disulfide bonds. These structural insights guide the design of modified variants with enhanced stability or targeted specificity. Current challenges in therapeutic applications include optimizing its pharmacokinetic profile and overcoming potential immunogenicity, while diagnostic applications leverage recombinant CD59A as a standard in flow cytometry for PNH testing.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
